Lupin has secured an exclusive deal with China's Gan Lee Pharmaceuticals to market and distribute Bofanglutide, a novel fortnightly GLP-1 receptor agonist, in India. The injectable drug is intended for treating type 2 diabetes and aiding weight management. Gan Lee's Bofanglutide is positioned as a potential first-in-class therapy, offering comparable or superior weight-loss outcomes to existing GLP-1 treatments with less frequent dosing, while also lowering blood glucose. This partnership aims to bolster Lupin's presence in the growing diabetes and obesity markets in India.